Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine in rare seizure disorders including Dravet syndrome and Lennox-Gastaut syndrome
NCT03936777Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Apr 2019
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, Lennox-Gastaut syndrome (LGS) and epileptic encephalopathy, sponsored by Zogenix, Inc. Primary endpoint: Treatment-emergent Adverse Events. Started Apr 2019; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epileptic encephalopathy
Beyond the preview
Go deeper on NCT03936777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936777.